Open Access Open Access  Restricted Access Subscription or Fee Access

Investigation on Plant Heparanase and its Inhibitors

Ramya Gunashekaran, Ragavi Sasikumar


Heparanase is an endoglycosidase which cleaves heparan sulfate (HS) and hence participates in degradation and remodelling of extracellular matrix (ECM). It further regulates multiple biological activities that enhance tumour growth, angiogenesis and metastasis. Heparanase expression is enhanced in almost all cancers examined including various carcinomas, sarcomas and haematological malignancies. In the present article, heparanase enzyme in plants and its activity against inhibitors was described. Here the heparanase enzyme and the E.coli enzyme (β-glucuronidase or GUS) was very similar. Hence the dilution process and quantitative assays were being done to examine its activity.


extracellular matrix (ECM), E.coli enzyme (β-glucuronidase), heparan sulphate (HS), tumour growth

Full Text:



Sanderson RD, Elkin M, Rapraeger AC, Ilan N, Vlodavsky I. Heparanase regulation of cancer, autophagy and inflamation therapy: New mechanisms and target for therapy. FEBS J. 2017; 284: 42–55p. doi: 10.1111/febs.13932.

Vlodavsky I, Singh P, Boyango I, Gutter-Kapon L, Elkin M, Sanderson RD, Ilan N. Heparanase: From basic research to therapeutic applications in cancer and inflamation. Drug Resist Updat. 2016; 29: 54–75p. doi: 10.1016/j.drup. 2016.10.001.

Li JP, Kusche-Gullberg M. Heperan sulfate: Biosynthesis, structure and function. Int Rev Cell Mol Biol. 2016; 325: 215–273p.

Rivara S, Milazzo FM, Giannini G. Heparanase: A rainbow pharmacological target associated to multiple pathologies including rare diseases. Future Med Cem. 2016; 8: 647–680p. doi:10.4155-fmc-2016-0012.

Simeonovic CJ, Ziolkowski AF, Wu Z, Choong FJ, Freeman C, Parish CR. Heparanase and autoimmune diabetes. Front Immunol. 2013; 4: 471p. doi:10.3389/fimmu.2013.00471.

Rabelink TJ, van den Berg BM, Garsen M, Wang G, Elkin M, Van der VJ. Heparanase: Roles in cell survival, extracellular matrix remodelling and the development of kidney disease. Nat Rev Nephrol. 2017; 13: 201–212p. doi: 10.1038/nrneph.2017.6.

Reliant J, Sanderson RD, Waguespack M, Barker SA, Long R, Carson DD, Marchetti D. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell division. J Biol Chem. 2004; 279(9): 8047–8055p.

Mahmood S, Beetz C, Tahir MM, Imran M, Mumtaz R, Bassmann I, Jahic A, Malik M, Nurnberg G, Hassan SAA, Rana S. First Hpse2 missense mutation in urofacial syndrome. Clin Genet. 2012; 81 (1): 88–92p.

Levy-Adam F, Feld S, Cohen-Kaplan V, Shteingauz A, Gross M, Arvatz G, Naroditsky I, Ilan N, Doweck I, Vlodavsky I. Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J Biol Chem. 2010; 285 (36): 28010–28019p.

Roberts NA, Woolf AS, Stuart HM, Thuret R, McKenzie EA, Newman WG, Hilton EN. Heparanase 2 mutated in urofacial syndrome, mediates peripheral neural development in xenopus. Hum Mol Genet. 2014; 23(16): 4302–4314p.

Merchant ZM, Kim YS, Rice KG, Linhardt R. Structure of heparan-derived tetrasaccharides. Biochem J. 1985; 229(2): 369–377p.

Davies GJ, Wilson KS, Henrissat B. Nomenclature for sugar- binding subsites in glycosyl hydrolases. Biochem J. 1997; 321 (Pt 2): 557–559p.

Fux L, Feibish N, Cohen-Kaplan V, Gingis-Velitski S, Feld S, Geffen C,Vlodavsky I, Ilan N. Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res. 2009; 69(5): 1758–1767p.

He YQ, Sutcliffe L, Bunting KL, Li J, Goodall KJ, Poon IKA, Hulett MD, Freeman C, Zafar A, McInnes RL, Taya T, Parish CR, Rao S. The endoglycosidase heparanase enters the nucules of T lymphocytes and moduliates H3 Methylation at actively transcribed genes via the inter play with key chromatin modifying enzymes. Transcripition. 2012; 3(3): 130–145p.

Thomson CA, Purushothaman A, Ramani VC, Vlodavsky I, Sanderson RD. Heparanase regulates secretion, composition, and function of tumour cell- derived exosomes. J Biol Chem. 2013; 288(14): 10093–10099p.

Hammond E, Handley P, Bredge K, Bytheway I. Mechanism of heparanase inhibition by the heparan sulfate mimetic PG 545 and 3 structural analogs. FEBS Open Biol. 2013; 3: 346–351p.

Page C. Heparan and related drugs: Beyond anticoagulant activity. ISRN Pharmacol. 2013; 2013: 910743.

Brennan TV, Lin L, Brandstadter JD, Rendell VR, Dredge K, Huang X, Yang Y. Heparan sufate Mimetic PG 545-mediated antilymphoma effects required TLR 9-dependent NK Cell activation J Clin Invest. 2016; 126(1): 207–219p.

Fero V, Liu L, Johnstone KD, Wimmer N, Karoli T, Handley P, Rowley J, Dredge K, Li CP, Hammond E, Davis K, Sarimaa L, Herenberg J, Bytheway I. Discovery of PG 545:a highly potent and simultaneously inhibitor of angiogenesis, tumor growth, and metastasis. J Med Chem. 2012; 55(8): 3804–3813p.

Winterhoff B, Freyer L, Hammond E, Giri S, Mondal S, Roy D, Teoman A, Mullany SA, Hoffmann R, von Bismarck A, Chiene J, Block MS, Millward M, Bampton D, Dredge K, Shridhar V. PG 545 enhances anticancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. Eur J Can. 2015; 51(7): 879–892p.


  • There are currently no refbacks.